Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…
The EMA has launched a consultation on the circumstances in which single-arm trials (SATs) – those without a control group – can be used to support marketing applications for medicines…